Skip to main content
Premium Trial:

Request an Annual Quote

DCN, Asahi Kasei Fibers Partner on Nanobeads for Assay Development

NEW YORK (GenomeWeb News) – DCN Diagnostics today announced a deal with Asahi Kasei Fibers for the distribution of Asahi's cellulose nanobead product in North America.

Additionally, DCN, formerly called Diagnostic Consulting Network, will be the preferred provider of original equipment manufacturing services to users of Asahi's product, called NanoAct, worldwide, except in Japan, where Asahi is based.

NanoAct products comprise a range of high-intensity colored beads, which can be multiplexed. They generate higher sensitivity, lower coefficients of variation, and better stability than other visual labels such as colloidal gold, DCN said.

"We believe that NanoAct will allow for the development of higher performing lateral flow tests," CDN President Brendan O'Farrell said in a statement. "Coupled with DCN's assay development, training and customer support capabilities, we believe that this product line will allow for product performance that can have significant impact in many markets."

Financial and other terms were not disclosed.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.